Get the Stockscreener App
2.35
4.47%
-0.11
Pre-market:
2.35
Atossa Therapeutics Inc stock is traded at $2.35, with a volume of 472.68K.
It is down -4.47% in the last 24 hours and down -51.55% over the past month.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
See More
Previous Close:
$2.46
Open:
$2.51
24h Volume:
472.68K
Relative Volume:
4.96
Market Cap:
$23.44M
Revenue:
-
Net Income/Loss:
$-34.77M
P/E Ratio:
-0.71
EPS:
-3.3097
Net Cash Flow:
$-29.79M
1W Performance:
-48.35%
1M Performance:
-51.55%
6M Performance:
-78.08%
1Y Performance:
-81.14%
1-Day Range:
$2.31
$2.51
1-Week Range:
$2.31
$4.59
52-Week Range:
$2.31
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.35 | 23.44M | 0 | -34.77M | -29.79M | -3.3097 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics brings medical innovation to Hudson Institute strategic discussions - Traders Union
Atossa Therapeutics (ATOS) Q1 2026 Earnings: Narrowing Losses with Positive EPS SurpriseRevenue Warning Signal - newsline.com
Atossa Therapeutics closes $4.5M registered direct offering By Investing.com - Investing.com Australia
Atossa Therapeutics closes $4.5M registered direct offering - Investing.com UK
Cancer-drug developer Atossa raises $4.5M, eyes $12M more - Stock Titan
Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering - Pulse 2.0
Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons - Traders Union
Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal - Stock Titan
Atossa Therapeutics prices up to $16.5M direct offering - MSN
Market Movers | Winners: XXII, PPCB, CCHH | Losers: BCPC, ATOS, BATL - Trefis
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Top Midday Decliners - Moomoo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims RiseAtossa Therapeutics (NASDAQ:ATOS), Big Tree C - Benzinga
Atossa Therapeutics Launches $16.5 Million Registered Direct Offering - marketscreener.com
Atossa Therapeutics stock tumbles on $4.5M stock offering - Investing.com UK
Atossa Therapeutics Announces Registered Direct Offering and Warrants - TipRanks
Atossa Therapeutics stock tumbles on $4.5M stock offering By Investing.com - Investing.com UK
Atossa Therapeutics raises $4.5M in registered direct offering - Investing.com
Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Atossa Therapeutics Prices Registered Direct Offering at $3.30, Netting About $4.1 Million - TradingView
Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale - Stock Titan
Biotech Atossa targets up to $16.5M to fund clinical work - Stock Titan
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment - Proactive financial news
Atossa Therapeutics (ATOS) Climbs 1.79% as Shares Approach Key Resistance at $4.78Wedge Breakout - newsline.com
Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts - Traders Union
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics - Yahoo Finance
Atossa Therapeutics (ATOS) Edges Higher on Modest Gains, Holds Above Key SupportReversal Trade - The Legal Advocate
ATOS News | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Cash from investing activities of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics (ATOS) Highlights Promising Data for (Z)-End - GuruFocus
Atossa presents preclinical data on breast cancer drug at ASCO - Investing.com UK
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer - Intellectia AI
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire
(Z)-Endoxifen hits ESR1 breast cancer mutations in new trial - Stock Titan
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics (ATOS) Holds Steady Near Support Amid Modest DeclineScalping Stock Signals - newsline.com
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - BioSpace
Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy - Traders Union
Atossa's New Research Findings on DMD - Intellectia AI
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) director granted 10,000 RSUs vesting after 2026 - Stock Titan
ATOS (ATOS) director Stephen Galli receives 10,000 RSU equity grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000 RSUs in stock award - Stock Titan
Atossa (NASDAQ: ATOS) director awarded 10,000 RSUs in stock grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000-share RSU award - Stock Titan
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):